Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Miami
About this trial
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
Eligibility criteria
Qualifiers
Men and women aged 18 years or older at the time of signing informed consent.
Able and willing to sign the informed consent form (ICF).
Ability to comply with the trial protocol.
LBCL or DLBCL, not otherwise specified (NOS)
Disqualifiers
Primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma at screening as confirmed by magnetic resonance imaging (MRI)/computed tomography (CT) scan (brain) and, if clinically indicated, by lumbar puncture.
Prior treatment with anti-cluster of differentiation 19 (anti-CD19) chimeric antigen receptor T-cell (CAR-T) therapy
Prior exposure to bispecific T-cell engaging antiCD20XCD3 antibodies
Prior autologous or allogenic stem cell transplant
Trial design
Treatments tested in this trial
- Epcoritamab
- Loncastuximab Tesirine
Treatment groups
26 Participants
are divided into 1 treatment groupLocations
1University of Miami33136, MiamiFlorida, United States
Sponsors and collaborators
University of Miami
Lead sponsor
ADC Therapeutics S.A.
Collaborator
Genmab
Collaborator
Source ClinicalTrials.gov